Xbrane Biopharma Logo

Xbrane Biopharma

Develops affordable biosimilars for serious diseases using patented, high-yield production tech.

XBRANE | ST

Overview

Corporate Details

ISIN(s):
SE0007789409 (+1 more)
LEI:
5493008DKD05APTKQO39
Country:
Sweden
Address:
RETZIUS VÄG, 8, 171 65 Solna
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Xbrane Biopharma is a biotechnology company specializing in the development of biosimilars, which are affordable, follow-on versions of approved biological drugs. The company's mission is to increase global access to treatments for serious diseases such as cancer, rheumatoid arthritis, and macular degeneration. Xbrane leverages a patented, high-yield production platform technology designed to significantly reduce manufacturing costs, aiming for up to an 80% cost reduction compared to standard systems. Its development portfolio includes biosimilar candidates targeting major biologic drug markets, such as Xlucane™ (a ranibizumab biosimilar) and BIIB801 (an adalimumab biosimilar).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 08:00
Share Issue/Capital Change
XBRANE BIOPHARMA AB (“XBRANE” OR THE “COMPANY”) HAS ACCORDING TO PREVIOUSLY ANN…
English 66.6 KB
2025-09-30 08:00
Share Issue/Capital Change
XBRANE BIOPHARMA AB ("XBRANE" ELLER "BOLAGET") HAR ENLIGT TIDIGARE OFFENTLIGGJO…
Swedish 66.6 KB
2025-09-10 08:30
Pre-Annual General Meeting Information
NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB
English 78.5 KB
2025-09-10 08:30
Pre-Annual General Meeting Information
KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB
Swedish 77.2 KB
2025-08-26 08:00
Interim Report
Swedish 1.3 MB
2025-08-26 08:00
Interim Report
English 1.3 MB
2025-07-31 21:00
Share Issue/Capital Change
Xbrane Biopharma AB ("Xbrane" eller "Bolaget") har enligt tidigare offentliggjo…
Swedish 64.5 KB
2025-07-31 21:00
Share Issue/Capital Change
Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously ann…
English 64.3 KB
2025-07-16 12:24
Major Shareholding Notification
Swedish 10.1 KB
2025-07-11 08:30
Prospectus
Xbrane publishes disclosure document regarding admission to trading of the newl…
English 80.6 KB
2025-07-11 08:30
Share Issue/Capital Change
Xbrane offentliggör undantagsdokument avseende upptagande till handel av de nye…
Swedish 72.9 KB
2025-07-03 11:00
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
Swedish 62.1 KB
2025-07-03 11:00
Share Issue/Capital Change
Announcement from extra general meeting in Xbrane Biopharma AB
English 62.4 KB
2025-06-10 05:15
Pre-Annual General Meeting Information
KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB
Swedish 69.0 KB
2025-06-10 05:15
Pre-Annual General Meeting Information
NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB
English 70.2 KB

Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-17 Karl Martin Erik Åmark Other Buy 1,864,223 318,782.13 SEK
2025-01-17 Karl Martin Erik Åmark Other Sell 1,864,223 315,053.69 SEK
2025-01-16 Siavash Bashiri Other Sell 1,519,932 260,212.36 SEK
2025-01-16 Siavash Bashiri Other Buy 1,500,000 256,500.00 SEK
2023-09-12 Karl Martin Erik Åmark Other Buy 4,000 129,000.00 SEK
2023-09-12 Karl Martin Erik Åmark Other Sell 4,000 128,200.00 SEK
2023-09-11 Karl Martin Erik Åmark Other Sell 2,000 62,140.00 SEK
2023-09-08 Siavash Bashiri Other Sell 5,890 194,959.00 SEK
2023-09-08 Karl Martin Erik Åmark Other Other 4,320 968.54 SEK
2023-09-08 Karl Martin Erik Åmark Other Other 4,320 N/A

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.